omniture
logo
Search
Accro Bioscience
Media Room

Latest News

rss

Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a cli...

2026-09-20 18:00 2625

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Ti...

2026-09-14 10:00 2188

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro...

2026-09-08 20:20 1605

Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona

NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotec...

2026-08-13 19:00 2783

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investo...

2026-05-19 08:00 6700

Accro Bioscience to Present Phase II Data of AC-201 for Plaque Psoriasis at the European Academy of Dermatology & Venereology Congress 2025 in Paris

NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ -- Accro Bioscience (Accropeutics), a clinic...

2025-09-04 20:24 3307

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis

* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing ...

2025-05-21 08:50 3539

Accropeutics Secured $12 Million in Series B Plus Financing

* Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with parti...

2025-03-14 16:23 4047

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechn...

2025-02-13 18:53 3415

Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

* Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerat...

2024-12-13 12:57 3487

TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I

SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small m...

2023-05-25 09:51 3522